June S&P 500 E-Mini futures (ESM24) are trending down -0.11% this morning as market participants awaited minutes of the Federal Reserve’s latest policy meeting as well as an earnings report from artificial...
Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...
Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET...
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...
Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting...
Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases...
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral...